AAV2 Capsid Mutations for Intravitreal Retinal Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors face challenges in effectively transducing retinal pigment epithelium and photoreceptor cells, particularly with intravitreal administration, leading to reduced infection efficiency and gene expression in inherited retinal diseases.
Innovation Solution
Engineering the AAV2 capsid protein with specific amino acid mutations (e.g., Q464V, A467P, D469N, I470M, R471A, D472V, S474G, Y500F, S501A, and optionally Y444F, Y730F) to enhance receptor affinity and tissue tropism, resulting in improved transduction efficiency and resistance to neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If AAV vectors are administered intravitreally for treating inherited retinal diseases, then the vector can reach retinal tissue, but the transduction efficiency is greatly reduced compared to subretinal or topical administration
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the AAV2 capsid protein VP1 through site-directed mutagenesis. Specific amino acid substitutions (Q464V, A467P, D469N, I470M, R471A, D472V, S474G, Y500F, S501A) were introduced to alter the capsid's receptor binding properties, enabling efficient retinal tissue transduction via intravitreal administration route
2Productivity
If AAV2 capsid protein is engineered with amino acid mutations to improve retinal tissue tropism, then transduction efficiency increases, but the complexity of vector engineering increases
Solution Approach 1:
The patent systematically changed the amino acid parameters of the capsid protein VP1 at specific positions to optimize retinal tissue targeting. The mutations were designed based on structural analysis and functional assays, achieving up to 50-fold increase in transduction efficiency while maintaining a manageable engineering complexity through focused site-directed mutagenesis
Solution Approach 2:
The patent applied local quality by introducing mutations at specific localized regions of the capsid protein VP1 that are critical for receptor binding and tissue tropism. This targeted approach allowed optimization of retinal targeting without requiring comprehensive modification of the entire capsid structure
3Quantity of substance
If high dose AAV2.7m8 is administered intravitreally, then more vector reaches retinal tissue, but it still fails to effectively transduce retinal pigment epithelium and photoreceptor cells
Solution Approach 1:
Instead of increasing the dose, the patent changed the quality parameter of the capsid protein through amino acid mutations. The modified capsid exhibited enhanced affinity for retinal tissue receptors, achieving effective transduction of RPE and photoreceptor cells at lower doses compared to wild-type AAV2.7m8
Data Source
AI summary
Provided are a method for engineering rAAV vectors to improve the retina tissue tropism, and infection and expression capability thereof and reduce the immunogenicity thereof, a vector obtained by the method, and the use thereof.